Ketamine and Quantum Psychiatry Dr
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Misuse of Drugs Act (MEI 2013).Fm
LAWS OF BRUNEI CHAPTER 27 MISUSE OF DRUGS 7 of 1978 9 of 1979 1984 Edition, Chapter 27 Amended by 10 of 1982 S 27/1982 S 20/1984 S 8/1987 S 36/1987 S 20/1989 S 24/1991 S 20/1992 S 28/1994 S 42/1998 S 60/1999 2001 Edition, Chapter 27 Amended by S 7/2002 S 59/2007 S 5/2008 S 12/2010 S 12/2012 REVISED EDITION 2013 B.L.R.O. 2/2013 LAWS OF BRUNEI Misuse of Drugs CAP. 27 1 LAWS OF BRUNEI REVISED EDITION 2013 CHAPTER 27 MISUSE OF DRUGS ARRANGEMENT OF SECTIONS Section PART I PRELIMINARY 1. Citation. 2. Interpretation. 2A. Appointment of Director and other officers of Bureau. 2B. Public servants. 2C. Powers of investigations of Bureau. 2D. Use of weapons. PART II OFFENCES INVOLVING CONTROLLED DRUGS 3. Trafficking in controlled drug. 3A. Possession for purpose of trafficking. 4. Manufacture of controlled drug. 5. Importation and exportation of controlled drug. B.L.R.O. 2/2013 LAWS OF BRUNEI 2 CAP. 27 Misuse of Drugs 6. Possession and consumption of controlled drug. 6A. Consumption of controlled drug outside Brunei Darussalam by permanent resident. 6B. Place of consumption need not be stated or proven. 7. Possession of pipes, utensils etc. 8. Cultivation of cannabis, opium and coca plants. 8A. Manufacture, supply, possession, import or export of equipment, materials or substances useful for manufacture of controlled drugs. 8B. Regulations and controlled substances. 9. Responsibilities of owners and tenants etc. 10. Abetments and attempts punishable as offences. 11. -
Wnt Signaling in Vertebrate Neural Development and Function
J Neuroimmune Pharmacol (2012) 7:774–787 DOI 10.1007/s11481-012-9404-x INVITED REVIEW Wnt Signaling in Vertebrate Neural Development and Function Kimberly A. Mulligan & Benjamin N. R. Cheyette Received: 18 June 2012 /Accepted: 10 September 2012 /Published online: 27 September 2012 # Springer Science+Business Media, LLC 2012 Abstract Members of the Wnt family of secreted signaling immature neurons migrate to populate different cortical proteins influence many aspects of neural development and layers, nuclei, and ganglia in the forebrain, midbrain, hind- function. Wnts are required from neural induction and axis brain, and spinal cord. Each mature neuron elaborates an formation to axon guidance and synapse development, and axon and numerous dendrites while forming hundreds to even help modulate synapse activity. Wnt proteins activate a thousands of synapses with other neurons, enabling electro- variety of downstream signaling pathways and can induce a chemical communication throughout the nervous system. similar variety of cellular responses, including gene tran- All these developmental processes must be coordinated to scription changes and cytoskeletal rearrangements. This re- ensure proper construction and function of the CNS, and view provides an introduction to Wnt signaling pathways this requires the coordinated developmental activity of a and discusses current research on their roles in vertebrate vast array of genes. neural development and function. Members of the Wnt family of secreted signaling proteins are implicated in every step of neural development men- Keywords Wnt signaling . Neural development . tioned above. Wnt proteins provide positional information CNS patterning . Axon guidance . Dendrite growth . within the embryo for anterior-posterior axis specification of Synapse formation . -
Glial Insulin Regulates Cooperative Or Antagonistic Golden Goal/Flamingo
RESEARCH ARTICLE Glial insulin regulates cooperative or antagonistic Golden goal/Flamingo interactions during photoreceptor axon guidance Hiroki Takechi1, Satoko Hakeda-Suzuki1*, Yohei Nitta2,3, Yuichi Ishiwata1, Riku Iwanaga1, Makoto Sato4,5, Atsushi Sugie2,3, Takashi Suzuki1* 1Graduate School of Life Science and Technology, Tokyo Institute of Technology, Yokohama, Japan; 2Center for Transdisciplinary Research, Niigata University, Niigata, Japan; 3Brain Research Institute, Niigata University, Niigata, Japan; 4Mathematical Neuroscience Unit, Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Japan; 5Laboratory of Developmental Neurobiology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan Abstract Transmembrane protein Golden goal (Gogo) interacts with atypical cadherin Flamingo (Fmi) to direct R8 photoreceptor axons in the Drosophila visual system. However, the precise mechanisms underlying Gogo regulation during columnar- and layer-specific R8 axon targeting are unknown. Our studies demonstrated that the insulin secreted from surface and cortex glia switches the phosphorylation status of Gogo, thereby regulating its two distinct functions. Non- phosphorylated Gogo mediates the initial recognition of the glial protrusion in the center of the medulla column, whereas phosphorylated Gogo suppresses radial filopodia extension by counteracting Flamingo to maintain a one axon-to-one column ratio. Later, Gogo expression ceases during the midpupal stage, thus allowing R8 filopodia to extend vertically into the M3 layer. These *For correspondence: results demonstrate that the long- and short-range signaling between the glia and R8 axon growth [email protected] (SH-S); cones regulates growth cone dynamics in a stepwise manner, and thus shapes the entire [email protected] (TS) organization of the visual system. Competing interests: The authors declare that no competing interests exist. -
Inaugural – Dissertation
INAUGURAL – DISSERTATION zur Erlangung der Doktorwürde der Naturwissenschaftlich-Mathematischen Gesamtfakultät der Ruprecht - Karls - Universität Heidelberg vorgelegt von Diplom-Biochemikerin Nadine Stephanie Kirsch geboren in Heidelberg Tag der mündlichen Prüfung: ……………………………………………. Analysis of novel Wnt pathway components acting at the receptor level Gutachter: Prof. Dr. Christof Niehrs Prof. Dr. Thomas Holstein Table of Contents Table of Contents 1. Summary .......................................................................................................................... 1 2. Zusammenfassung ........................................................................................................... 2 3. Introduction ..................................................................................................................... 3 3.1 Wnt signaling transduction cascades ......................................................................... 3 3.1.1 Wnt/β-catenin signaling ...................................................................................... 4 3.1.2 Wnt/PCP signaling ............................................................................................... 6 3.2 Wnt/β-catenin signaling regulation at the receptor level ......................................... 8 3.2.1 Wnt receptors ...................................................................................................... 8 3.2.2 Extracellular modifiers ...................................................................................... -
Pharmacogenetics of Ketamine Metabolism And
Pharmacogenetics of Ketamine Metabolism and Immunopharmacology of Ketamine Yibai Li B.HSc. (Hons) Discipline of Pharmacology, School of Medical Sciences, Faculty of Health Sciences, The University of Adelaide September 2014 A thesis submitted for the Degree of PhD (Medicine) Table of contents TABLE OF CONTENTS .............................................................................................. I LIST OF FIGURES ....................................................................................................IV LIST OF TABLES ......................................................................................................IV ABSTRACT ............................................................................................................... V DECLARATION .......................................................................................................VIII ACKNOWLEDGEMENTS ..........................................................................................IX ABBREVIATIONS .....................................................................................................XI CHAPTER 1. INTRODUCTION .................................................................................. 1 1.1 A historical overview of ketamine ........................................................................................ 1 1.2 Structure and Chemistry ....................................................................................................... 3 1.3 Classical analgesic mechanisms of ketamine ................................................................... -
A Role for Atypical Cadherincelsr3in Hippocampal Maturation And
The Journal of Neuroscience, October 3, 2012 • 32(40):13729–13743 • 13729 Development/Plasticity/Repair A Role for Atypical Cadherin Celsr3 in Hippocampal Maturation and Connectivity Jia Feng,1 Ying Xu,1 Meizhi Wang,1 Yiwen Ruan,1 Kwok-Fai So,1,2 Fadel Tissir,3 Andre Goffinet,3 and Libing Zhou1 1Joint Laboratory for Brain Function and Health, Jinan University and the University of Hong Kong, Medical School of Jinan University, Guangzhou 510632, People’s Republic of China, 2Department of Anatomy, the University of Hong Kong, Pokfulam, Hong Kong SAR, People’s Republic of China, and 3Institute of Neuroscience, Universite´ Catholique de Louvain, B1200 Brussels, Belgium Atypical cadherin Celsr3, a regulator of planar cell polarity, is critical for the development of the axonal blueprint. We previously showed that expression of Celsr3 is necessary to establish forebrain connections such as the anterior commissure and thalamocortical and corticospinal tracts. The requirement for Celsr3 during hippocampal wiring and its action in the hippocampus remain largely unex- plored. Here, we compared the connectivity and maturation of the hippocampal formation in Celsr3͉Foxg1 and Celsr3͉Dlx mice. Celsr3 is inactivated in the whole telencephalon, including the hippocampal primordium, in Celsr3͉Foxg1 mice, and in the early basal telenceph- alon, including ganglionic eminences and ventral diencephalon, in Celsr3͉Dlx mice. Behavioral tests showed that both mutants were hyperactive and had impaired learning and memory. Abnormal cytoarchitecture of CA1, CA3, and dentate gyrus was found in the Celsr3͉Foxg1 mutant, in which afferent and efferent hippocampal pathways, as well as intrinsic connections, were dramatically disrupted. In Celsr3͉Dlx mutant mice, hippocampal cytoarchitecture was mildly affected and extrinsic and intrinsic connectivity moderately dis- turbed. -
Quantification of Drugs for Drug-Facilitated Crimes in Human Urine
Quantification of Drugs for Drug-Facilitated Crimes in Human Urine by Liquid Chromatography Tandem Mass Spectrometry Claudio De Nardi1, Anna Morando2, Anna Del Plato2 1Thermo Fisher Scientific, Dreieich, Germany; 2Ospedale “La Colletta”, Arenzano, Italy Overview TABLE 1. Concentrations of calibrators TABLE 3. Concentration range, intercept, slope and correlation factor (R2) Purpose: To implement a liquid chromatography tandem mass spectrometry method for forensic toxicology for the CAL CAL CAL CAL CAL CAL CAL Analyte Units Calibration quantification of drugs for drug-facilitated crimes in human 1 2 3 4 5 6 7 Analyte Intercept Slope R2 urine on a Thermo Scientific™ TSQ Access MAX™ triple stage Range Ketamine mass spectrometer; the method includes ketamine, its Ketamine 5 – 200 ng/mL -0.002 0.004 0.999 metabolites norketamine and dehydronorketamine, Norketamine phencyclidine and γ-butyrolactone (GBL); the method is also Norketamine 5 – 200 ng/mL 0.000 0.003 0.998 Dehydro ng/mL 5 10 20 50 100 200 N/A suitable for the detection of γ-hydroxybutyric acid (GHB) at norketamine Dehydronorketamine 5 – 200 ng/mL -0.001 0.002 0.999 physiological levels. Phencyclidine Phencyclidine 5 – 200 ng/mL 0.000 0.003 0.999 Methods: Following extraction using three volumes of GBL µg/mL 1 2 5 10 20 50 100 GBL 1 – 100 µg/mL -0.001 0.008 0.999 methanol containing 0.1% formic acid, samples were injected onto a Thermo Scientific™ Accela™ 600 HPLC system connected to a TSQ Access MAX triple stage mass Mass Spectrometry Figure 1. Calibration curve forGBL GBL spectrometer using a heated electrospray source. -
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209 -
Ketamine Homogeneous Enzyme Immunoassay (HEIA™)
Ketamine Homogeneous Enzyme Immunoassay (HEIA™) Exclusively from Immunalysis Formula: C13H16CINO Semi-Quantitative or Qualitative Testing Systematic Name: (RS)- 2- (2- chlorophenyl)- 2- (methylamino)cyclohexanone Accurate and reliable Brand Names: Ketanest®, Ketaset®, Ketalar® Ready to use About Ketamine: Ketamine is an anesthetic agent used in the United States since 1972 for veterinary and pediatric medicine. It is also used in the treatment of depression and postoperative pain management. However, in recent years it has gained popularity as a street drug used at clubs and raves due to its hallucinogenic effects. Administration: Oral; intravenous; intramuscular; insufflation Elimination: Ketamine metabolizes by N-demethylation to Norketamine and further dehydrogenates to Dehydronorketamine. After 72 hours of a single dose, 2.3% of Ketamine is unchanged, 1.6% is Norketamine, 16.2% is Dehydronorketamine, and 80% is hydroxylated derivatives of Ketamine.1,2 Abuse Potential: An overdose can cause unconsciousness and dangerously slowed breathing. 1) R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, Fourth Edition, p. 412-414. 2) K. Moore, J.Skerov, B.Levine, and A.Jacobs, Urine Concentrations of Ketamine and Norketamine Following Illegal Consumption, J.Anal, Toxicol. 25: 583-588 (2001). Ketanest® is a registered trademark of Pfizer, Inc., Ketaset® is a trademark of ZOETIS W LLC., Ketalar® is a trademark of PAR STERILE PRODUCTS, LLC. Tel 909.482.0840 | Toll Free 888.664.8378 | Fax 909.482.0850 ISO13485:2003 www.immunalysis.com CERTIFIED -
The Cytoplasmic LIM Domain Protein Espinas Contributes to Photoreceptor Layer Selection in the Visual System
biology Article The Cytoplasmic LIM Domain Protein Espinas Contributes to Photoreceptor Layer Selection in the Visual System 1,2, 1,2, 1 Alejandra Fernández-Pineda y , Martí Monge-Asensio y , Martín Rios and Marta Morey 1,2,* 1 Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain; [email protected] (A.F.-P.); [email protected] (M.M.-A.); [email protected] (M.R.) 2 Institut de Biomedicina (IBUB), Universitat de Barcelona, 08028 Barcelona, Spain * Correspondence: [email protected] Equal contribution. y Received: 27 November 2020; Accepted: 12 December 2020; Published: 14 December 2020 Simple Summary: One of the central questions in neurobiology is how neurons discriminate between one another during circuit assembly. A common strategy of many nervous systems is the organization of brain regions in layers, to facilitate that neurons encounter a limited repertoire of synaptic partners. The fly visual system, which is structured in layers like many regions of the vertebrate brain, is used to identify cell surface molecules that mediate recognition between neurons and allow them to extend to specific layers. However, little is known about the intracellular pathways that link cell surface molecules to the cytoskeleton to determine whether or not to stabilize in a layer. Flamingo and its vertebrate homologs CELSR1/2 are cell surface molecules with widespread roles in neurite growth. In the fly visual system in particular, Flamingo regulates layer selection of a particular neuronal type. Our data suggests that in this context, Flamingo signals to the cytoskeleton through the conserved cytoplasmic molecule Espinas/PRICKLE2. Given that Flamingo and Espinas, as well as their respective vertebrate homologs, are broadly expressed in the nervous system, elucidating the interactions between them can reveal conserved mechanisms and provide valuable insights into the assembly of neural circuits. -
A Clickable Analogue of Ketamine Retains NMDA Receptor Activity
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2016 A clickable analogue of ketamine retains NMDA receptor activity, psychoactivity, and accumulates in neurons Christine Emnett Washington University School of Medicine in St. Louis Hairong Li Washington University School of Medicine in St. Louis Xiaoping Jiang Washington University School of Medicine in St. Louis Ann Benz Washington University School of Medicine in St. Louis Joseph Boggiano Washington University School of Medicine in St. Louis See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Recommended Citation Emnett, Christine; Li, Hairong; Jiang, Xiaoping; Benz, Ann; Boggiano, Joseph; Conyers, Sara; Wozniak, David F.; Zorumski, Charles F.; Reichert, David E.; and Mennerick, Steven, ,"A clickable analogue of ketamine retains NMDA receptor activity, psychoactivity, and accumulates in neurons." Scientific Reports.6,. (2016). https://digitalcommons.wustl.edu/open_access_pubs/5464 This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact [email protected]. Authors Christine Emnett, Hairong Li, Xiaoping Jiang, Ann Benz, Joseph Boggiano, Sara Conyers, David F. Wozniak, Charles F. Zorumski, David E. Reichert, and Steven Mennerick This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/open_access_pubs/5464 www.nature.com/scientificreports OPEN A Clickable Analogue of Ketamine Retains NMDA Receptor Activity, Psychoactivity, and Accumulates in Received: 15 June 2016 Accepted: 15 November 2016 Neurons Published: 16 December 2016 Christine Emnett1,2,*, Hairong Li3,*, Xiaoping Jiang1, Ann Benz1, Joseph Boggiano1, Sara Conyers1, David F. -
RESEARCH PROTOCOL Role of CYP2B6 Polymorphisms In
RESEARCH PROTOCOL Role of CYP2B6 polymorphisms in ketamine metabolism and clearance Evan D. Kharasch, M.D., Ph.D. Russell D. and Mary B. Shelden Professor of Anesthesiology Director, Division of Clinical and Translational Research Washington University School of Medicine Department of Anesthesiology 660 S. Euclid Ave., Campus Box 8054 St. Louis, Mo. 63110 Voice: (314) 362-8796 Fax: (314) 747-3371 E-mail: [email protected] Original Version: July 9, 2013 2 1. SYNOPSIS Study Title Role of CYP2B6 polymorphisms in ketamine metabolism and clearance Objective To determine the effects of cytochrome P4502B6 (CYP2B6) genetic variants on ketamine metabolism and clearance Study Design Single-center, open label, single-session study to evaluate ketamine pharmaco- kinetics in subjects with known CYP2B6 genotype Study Period Planned enrollment duration: Approximately 3 months. Planned study duration: 1 day per subject Number of Patients Approximately 40 healthy volunteers identified by CYP2B6 genotyping by HRPO-approved screening Inclusion and Inclusion Criteria Exclusion Criteria a) 18-50 yr old b) CYP2B6*1/*1, CYP2B6*1/*6 or CYP2B6*6/*6 genotype c) Good general health with no remarkable medical conditions d) BMI < 33 e) Provide informed consent Exclusion Criteria a) Known history of liver or kidney disease b) Use of prescription or non-prescription medications, herbals, foods or chemicals known to be metabolized by or affecting CYP2B6 c) Females who are pregnant or nursing d) Known history of drug or alcohol addiction (prior or present addiction or treatment for addiction) e) Direct physical access to and routine handling of addicting drugs in the regular course of duty (a routine exclusion from studies of drugs with addiction potential) Study Medication Subjects will be studied on one occasion at Washington University in St.